MCRPC

Results: 35



#Item
1Intranet “Internal News” Posting & Leading Edge article, authored by Kathy, Dede or Rob

Intranet “Internal News” Posting & Leading Edge article, authored by Kathy, Dede or Rob

Add to Reading List

Source URL: www.cmsastellas.ca

Language: English - Date: 2015-04-16 08:07:47
2BioMed Research International Special Issue on Optimal Sequencing and/or Combination of the New Drugs for mCRPC  CALL FOR PAPERS

BioMed Research International Special Issue on Optimal Sequencing and/or Combination of the New Drugs for mCRPC CALL FOR PAPERS

Add to Reading List

Source URL: downloads.hindawi.com

Language: English - Date: 2015-03-15 04:33:13
3«ETTORE MAJORANA» FOUNDATION AND CENTRE FOR SCIENTIFIC CULTURE TO PAY A PERMANENT TRIBUTE TO GALILEO GALILEI, FOUNDER OF MODERN SCIENCE AND TO ENRICO FERMI, THE “ITALIAN NAVIGATOR”, FATHER OF THE WEAK FORCES INTERN

«ETTORE MAJORANA» FOUNDATION AND CENTRE FOR SCIENTIFIC CULTURE TO PAY A PERMANENT TRIBUTE TO GALILEO GALILEI, FOUNDER OF MODERN SCIENCE AND TO ENRICO FERMI, THE “ITALIAN NAVIGATOR”, FATHER OF THE WEAK FORCES INTERN

Add to Reading List

Source URL: www.ccsem.infn.it

Language: English - Date: 2015-05-13 10:13:11
4Benzoates / Carbamates / Abiraterone / Antiandrogens / Pyridines / Prostate cancer / Docetaxel / Cyclophosphamide / Cabazitaxel / Medicine / Chemistry / Organic chemistry

6.1 ABIRATERONE ACETATE, tablet, 250 mg, Zytiga®, Janssen-Cilag Pty Ltd Purpose of Application Authority required listing for abiraterone for treatment of metastatic castrate-resistant prostate cancer (mCRPC) after tre

Add to Reading List

Source URL: www.pbs.gov.au

Language: English - Date: 2014-11-12 19:13:31
5Daniel P. Petrylak, M.D.  CURRICULUM VITAE Date of Revision: February 7, 2014 Name:

Daniel P. Petrylak, M.D. CURRICULUM VITAE Date of Revision: February 7, 2014 Name:

Add to Reading List

Source URL: yale-faculty.photobooks.com

Language: English - Date: 2014-02-07 12:35:16
6For UK consumer and medical media Embargoed until[removed]Thursday 11th July 2013 New treatment for the management of advanced prostate cancer after failure on first-line hormonal treatments and docetaxel chemotherapy, now

For UK consumer and medical media Embargoed until[removed]Thursday 11th July 2013 New treatment for the management of advanced prostate cancer after failure on first-line hormonal treatments and docetaxel chemotherapy, now

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2013-07-11 01:00:53
7XTANDI™▼ (ENZALUTAMIDE) AUTHORISED IN THE EUROPEAN UNION (EU) FOR ADVANCED PROSTATE CANCER Enzalutamide authorised in European Union (EU) for the treatment of adult men with metastatic castration-resistant prostate c

XTANDI™▼ (ENZALUTAMIDE) AUTHORISED IN THE EUROPEAN UNION (EU) FOR ADVANCED PROSTATE CANCER Enzalutamide authorised in European Union (EU) for the treatment of adult men with metastatic castration-resistant prostate c

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2013-06-23 21:02:09
8Microsoft Word - M0trial12 2 13final (3).docx

Microsoft Word - M0trial12 2 13final (3).docx

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2013-12-03 18:32:13
9Issues Concerning Development of Products for Treatment of Non-Metastatic CastrationResistant Prostate Cancer (NM-CRPC) FDA Presentation ODAC Meeting

Issues Concerning Development of Products for Treatment of Non-Metastatic CastrationResistant Prostate Cancer (NM-CRPC) FDA Presentation ODAC Meeting

Add to Reading List

Source URL: www.fda.gov

Language: English
10ODAC Briefing for NM-CRPC

ODAC Briefing for NM-CRPC

Add to Reading List

Source URL: www.fda.gov

Language: English